000294360 001__ 294360
000294360 005__ 20241103013613.0
000294360 0247_ $$2doi$$a10.1038/s41416-024-02858-6
000294360 0247_ $$2pmid$$apmid:39342063
000294360 0247_ $$2ISSN$$a0007-0920
000294360 0247_ $$2ISSN$$a1532-1827
000294360 0247_ $$2altmetric$$aaltmetric:168774263
000294360 037__ $$aDKFZ-2024-02193
000294360 041__ $$aEnglish
000294360 082__ $$a610
000294360 1001_ $$00000-0001-9050-7590$$aCastro-Espin, Carlota$$b0
000294360 245__ $$aPrognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study.
000294360 260__ $$aEdinburgh$$bNature Publ. Group$$c2024
000294360 3367_ $$2DRIVER$$aarticle
000294360 3367_ $$2DataCite$$aOutput Types/Journal article
000294360 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1730276456_10605
000294360 3367_ $$2BibTeX$$aARTICLE
000294360 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294360 3367_ $$00$$2EndNote$$aJournal Article
000294360 520__ $$aInflammation influences tumour progression and cancer prognosis, but its role preceding breast cancer (BC) and its prognostic implications remain inconclusive.We studied pre-diagnostic plasma inflammatory biomarkers in 1538 women with BC from the EPIC study. Cox proportional hazards models assessed their relationship with all-cause and BC-specific mortality, adjusting for tumour characteristics and lifestyle factors.Over a 7-year follow-up after diagnosis, 229 women died, 163 from BC. Elevated IL-6 levels were associated with increased all-cause mortality risk (HR1-SD 1.25, 95% CI 1.07-1.47). Among postmenopausal, IL-6 was associated with higher all-cause (HR1-SD 1.41, 95% CI 1.18-1.69) and BC-specific mortality (HR1-SD 1.31, 95% CI 1.03-1.66), (PHeterogeneity (pre/postmenopausal) < 0.05 for both), while IL-10 and TNFα were associated with all-cause mortality only (HR1-SD 1.19, 95% CI 1.02-1.40 and HR1-SD 1.28, 95% CI 1.06-1.56). Among ER+PR+, IL-10 was associated with all-cause and BC-specific mortality (HR1-SD 1.35, 95% CI 1.10-1.65 and HR1-SD 1.42 95% CI 1.08-1.86), while TNF-α was associated with all-cause mortality in HER2- (HR1-SD 1.31, 95% CI 1.07-1.61). An inflammatory score predicted higher all-cause mortality, especially in postmenopausal women (HR1-SD 1.30, 95% CI 1.07-1.58).Higher pre-diagnosis IL-6 levels suggest poorer long-term survival among BC survivors. In postmenopausal survivors, elevated IL-6, IL-10, and TNFα and inflammatory scores seem to predict all-cause mortality.
000294360 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000294360 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294360 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000294360 650_7 $$2NLM Chemicals$$aInterleukin-6
000294360 650_7 $$0130068-27-8$$2NLM Chemicals$$aInterleukin-10
000294360 650_7 $$2NLM Chemicals$$aTumor Necrosis Factor-alpha
000294360 650_7 $$2NLM Chemicals$$aIL6 protein, human
000294360 650_7 $$2NLM Chemicals$$aIL10 protein, human
000294360 650_2 $$2MeSH$$aHumans
000294360 650_2 $$2MeSH$$aFemale
000294360 650_2 $$2MeSH$$aBreast Neoplasms: mortality
000294360 650_2 $$2MeSH$$aBreast Neoplasms: blood
000294360 650_2 $$2MeSH$$aBreast Neoplasms: diagnosis
000294360 650_2 $$2MeSH$$aBreast Neoplasms: pathology
000294360 650_2 $$2MeSH$$aMiddle Aged
000294360 650_2 $$2MeSH$$aPrognosis
000294360 650_2 $$2MeSH$$aInflammation: blood
000294360 650_2 $$2MeSH$$aInflammation: mortality
000294360 650_2 $$2MeSH$$aBiomarkers, Tumor: blood
000294360 650_2 $$2MeSH$$aInterleukin-6: blood
000294360 650_2 $$2MeSH$$aAged
000294360 650_2 $$2MeSH$$aPostmenopause: blood
000294360 650_2 $$2MeSH$$aCohort Studies
000294360 650_2 $$2MeSH$$aInterleukin-10: blood
000294360 650_2 $$2MeSH$$aAdult
000294360 650_2 $$2MeSH$$aTumor Necrosis Factor-alpha: blood
000294360 650_2 $$2MeSH$$aProportional Hazards Models
000294360 7001_ $$aCairat, Manon$$b1
000294360 7001_ $$aNavionis, Anne-Sophie$$b2
000294360 7001_ $$00000-0003-0481-2893$$aDahm, Christina C$$b3
000294360 7001_ $$aAntoniussen, Christian S$$b4
000294360 7001_ $$aTjønneland, Anne$$b5
000294360 7001_ $$aMellemkjær, Lene$$b6
000294360 7001_ $$aMancini, Francesca Romana$$b7
000294360 7001_ $$aHajji-Louati, Mariem$$b8
000294360 7001_ $$aSeveri, Gianluca$$b9
000294360 7001_ $$0P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6$$aLe Cornet, Charlotte$$b10$$udkfz
000294360 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b11$$udkfz
000294360 7001_ $$aSchulze, Matthias B$$b12
000294360 7001_ $$aMasala, Giovanna$$b13
000294360 7001_ $$aAgnoli, Claudia$$b14
000294360 7001_ $$aSacerdote, Carlotta$$b15
000294360 7001_ $$aCrous-Bou, Marta$$b16
000294360 7001_ $$aSánchez, Maria-Jose$$b17
000294360 7001_ $$aAmiano, Pilar$$b18
000294360 7001_ $$aChirlaque, María-Dolores$$b19
000294360 7001_ $$aGuevara, Marcela$$b20
000294360 7001_ $$00000-0002-1932-7463$$aSmith-Byrne, Karl$$b21
000294360 7001_ $$00000-0001-6517-1300$$aHeath, Alicia K$$b22
000294360 7001_ $$aChristakoudi, Sofia$$b23
000294360 7001_ $$aGunter, Marc J$$b24
000294360 7001_ $$aRinaldi, Sabina$$b25
000294360 7001_ $$aAgudo, Antonio$$b26
000294360 7001_ $$aDossus, Laure$$b27
000294360 773__ $$0PERI:(DE-600)2002452-6$$a10.1038/s41416-024-02858-6$$gVol. 131, no. 9, p. 1496 - 1505$$n9$$p1496 - 1505$$tBritish journal of cancer$$v131$$x0007-0920$$y2024
000294360 909CO $$ooai:inrepo02.dkfz.de:294360$$pVDB
000294360 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000294360 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000294360 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000294360 9141_ $$y2024
000294360 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-22$$wger
000294360 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000294360 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000294360 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-22
000294360 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000294360 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-22
000294360 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-22
000294360 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000294360 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-22
000294360 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-22
000294360 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-22
000294360 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-22
000294360 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J CANCER : 2022$$d2023-10-22
000294360 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-22
000294360 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-22
000294360 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J CANCER : 2022$$d2023-10-22
000294360 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000294360 980__ $$ajournal
000294360 980__ $$aVDB
000294360 980__ $$aI:(DE-He78)C020-20160331
000294360 980__ $$aUNRESTRICTED